Study on Chloroquine and Hydroxychloroquine in SARS-Cov-2: Repurposing the old Drugs against Today’s Deadly Disease | Chapter 19 | New Frontiers in Medicine and Medical Research Vol. 4

 Introduction: Chloroquine (CQ) and Hydroxychloroquine (HCQ) have gained a lot of traction as potential COVID-19 treatments. The medicine has been approved in India for the prophylaxis of asymptomatic health workers who are treating suspected or confirmed COVID-19 cases, as well as asymptomatic household contacts of confirmed patients. The Food and Drug Administration (FDA) in the United States has granted HCQ an Emergency Use Authorization (EUA) to treat COVID-19.

Materials and Procedures: In COVID-19, we give a database of trials using these drugs.

Discussion: In early 15 registered clinical trials of CQ and HCQ in COVID -19 positive patients in China, the drugs were found to be superior to the control treatment in preventing pneumonia exacerbation, improving lung imaging findings, promoting virus-negative conversion, and shortening the disease course. A international registry investigation of HCQ with or without a macrolide for the treatment of COVID-19 published online in Lancet on May 22, 2020, found no favourable findings. When HCQ was administered to treat COVID-19, the study found a worse in-hospital survival rate and a higher frequency of ventricular arrhythmias. In light of this report, the WHO paused the HCQ arm of its global clinical trial ‘Solidarity' on May 26, 2020, and experiments with HCQ/CQ for COVID were also halted. The Lancet paper sparked debate until the authors retracted the publication on June 4th, 2020.

Conclusions: Repurposing these pharmaceuticals is debatable until the findings of the WHO fast track ‘Solidarity' clinical trial and additional randomised clinical trials are released.

Author (S) Details

Kavita M. Jaiswal
Department of Pharmacology, Government Medical College, Gondia, Maharashtra India.

Sujata Dudhgaonkar
Department of Pharmacology, Government Medical College, Gondia, Maharashtra India.

Latesh Raghute
Department of Pharmacology, Government Medical College, Gondia, Maharashtra India.

Mahek S. Kewalramani
Department of Pharmacology, Government Medical College, Gondia, Maharashtra India.            

Lohit S. Vaishnao
Department of Pharmacology, Government Medical College, Gondia, Maharashtra India.

View Book :- https://stm.bookpi.org/NFMMR-V4/article/view/2898